首页> 美国卫生研究院文献>ACS AuthorChoice >Competition Studies Confirm Two Major Barriers ThatCan Preclude the Spread of Resistance to Quorum-Sensing Inhibitorsin Bacteria
【2h】

Competition Studies Confirm Two Major Barriers ThatCan Preclude the Spread of Resistance to Quorum-Sensing Inhibitorsin Bacteria

机译:竞争研究确定了两个主要障碍可以排除对群体感应抑制剂的抗药性在细菌中

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The growing threat of antibiotic resistance necessitates the development of novel antimicrobial therapies. Antivirulence agents that target group-beneficial traits in microorganisms (i.e., phenotypes that help the cells surrounding the producer cell instead of selfishly benefiting only the producer cell) represent a new antimicrobial approach that may be robust against the spread of resistant mutants. One prominent group-beneficial antivirulence target in bacteria is quorum sensing (QS). While scientists are producing new QS inhibitors (QSIs) at an increasing pace for use as research tools and potential therapeutic leads, substantial work remains in empirically demonstrating a robustness against resistance. Herein we report the results of in vitro competition studies in Pseudomonas aeruginosa that explicitly confirm that two separate barriers can impede the spread of resistance to QSIs: (1) insufficient native QS signal levels prevent rare QSI-resistant bacteria from expressing their QS regulon, and (2) group-beneficial QS-regulated phenotypes produced by resistant bacteria are susceptible to cheating by QSI-sensitiveneighbors, even when grown on a solid substrate with limited mixingto mimic infected tissue. These results underscore the promise ofQSIs and other antivirulence molecules that target group beneficialtraits as resistance-robust antimicrobial treatments and provide supportfor their further development.
机译:抗生素耐药性的日益增长的威胁使得必须开发新的抗微生物疗法。靶向微生物中有益于群体的特征的抗毒剂(即帮助生产者细胞周围细胞的表型而不是仅自私地使生产者细胞受益的表型)代表了一种新的抗微生物方法,该方法可以有效抵抗耐药突变体的扩散。细菌中一个重要的对群体有益的抗毒力目标是群体感应(QS)。尽管科学家们正在以越来越高的速度生产新的QS抑制剂(QSI)用作研究工具和潜在的治疗先导,但在经验上仍需开展大量工作,以证明其具有抗药性。本文中,我们报告了铜绿假单胞菌体外竞争研究的结果,该研究明确证实了两个单独的障碍可以阻碍对QSI的抗性扩散:(1)天然QS信号水平不足会阻止稀有的QSI抗性细菌表达其QS调节子,以及(2)由耐药细菌产生的有益于群体的QS调节表型易受QSI敏感的欺骗邻居,即使在有限混合的固体基质上生长模仿受感染的组织。这些结果强调了QSI和其他针对小组的抗毒分子有益性状作为抗药性强的抗菌药物并提供支持为他们的进一步发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号